MAPK in Cancers: From Signalling Pathways to Therapeutic Targets
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2023) | Viewed by 20343
Special Issue Editor
2.Department of Endocrinology, Centro Hospitalar Universitario S João, (S Joao University Hospital Center) 4200‐135 Porto, Portugal.
Interests: adrenal cortex carcinoma; adrenal tumors; Cushing’s syndrome; incidentalomas; pheocromocytomas
Special Issue Information
Dear Colleagues,
The mitogen-activated protein kinase (MAPK) is an evolutionary-conserved signaling cascade that plays a crucial role in cell signal transduction in response to a range of extracellular and intracellular stimuli, both in physiological and pathological conditions.
The MAPK/ERK pathway is the best studied of the mammalian MAPK pathways, and it is dysregulated in a large number of human cancers. This pathway has many diverse effects in the regulation of oncogenesis, tumor progression, differentiation, and apoptosis. Significant efforts have led to the clinical success of some MAPK-ERK pathway inhibitors. However, the clinical benefits of these inhibitors are frequently compromised by the development of drug resistance.
In this Special Issue, we will publish reviews and original research that provide new insights into the MAPK/ERK signaling pathway in cancers, how it can be targeted therapeutically, and how it is possible to overcome the already observed drug resistance.
Dr. Duarte Pignatelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- MAPK/ERK pathway
- Human cancers
- MAPK/ERK pathway component mutations
- MAPK/ERK pathway-targeted therapies
- Drug resistance
- Combination therapy
- MAPK/ERK pathway enrollment in tumor metabolic reprogramming
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
